Email:
global@GCP-ClinPlus.com
Cell and Gene Therapy (CGT) is transforming the treatment landscape for difficult-to-treat diseases, particularly cancers and rare disorders. However, the path from lab to market remains steep—clinical-stage success rates hover at just 5.3%, dropping to 3.2% for oncology indications. Products with orphan drug designation fare better at 9.4% ^[1]^.
These numbers tell a clear story: scientific rigor in trial design and strict regulatory compliance are make-or-break factors for CGT development success. As more CGT products advance into confirmatory trials and marketing applications worldwide, mastering Good Clinical Practice (GCP) and navigating regulatory inspections have become mission-critical for sponsors and clinical teams alike.
This article integrates the latest global regulatory trends with hands-on clinical experience, offering a practical, design-to-inspection roadmap for CGT clinical trial compliance.
GCP rests on two fundamental pillars: protecting subject rights and ensuring data reliability ^[2]^. In CGT trials, these principles demand deeper implementation due to the unique nature of the products—personalized manufacturing, complex mechanisms, not yet fully understood long-term safety profiles, and specialized delivery methods.
An effective quality management system for CGT trials rests on three interdependent pillars:
Ethics: Transparent informed consent, scientifically sound design, minimized risk
Quality: SOP-driven closed-loop management for investigational products, adverse events, monitoring, and auditing
Data: Full adherence to ALCOA+ principles—data must be Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Enduring, and Available ^[3]^
CGT trials typically target well-defined patient populations, making inclusion/exclusion criteria particularly critical—and complex. Investigators must maintain complete, auditable supporting evidence for every enrolled subject: prior medical records, medication histories, imaging and pathology reports, lab results. This documentation confirms that each subject truly meets protocol criteria and prevents enrollment deviations ^[4]^.
For CGT products targeting small populations or rare diseases, the FDA's September 2025 draft guidance on "Innovative Designs for Cellular and Gene Therapy Products in Small Populations" offers valuable flexibility. Sponsors should engage regulators early to explore fit-for-purpose designs: single-arm trials with external controls, adaptive designs, Bayesian methods, or master protocols.
The key is ensuring scientific validity of subject selection—carefully considering the treatment landscape, symptom profiles, and population representativeness to generate robust conclusions despite small sample sizes ^[5]^.
CGT products carry unique safety risks: CRS, ICANS, insertional mutagenesis, GvHD ^[6]^. Trial teams must be equipped to rapidly identify, appropriately manage, and promptly report these events—with closed-loop management throughout.
AE identification and recording: Systematically capture all AEs; ensure CRF data perfectly matches source data—no omissions, no errors ^[4]^
Lab result review and management: Promptly review all lab data; document and address clinically significant abnormalities with appropriate interventions; retain complete records ^[4]^
Source document management: Medical record systems must maintain robust audit trails—creator, creation time, modifier, modification time, pre-modification data—fully ALCOA+ compliant ^[3,4]^
Safety reporting compliance: Sponsors must submit SUSARs and DSURs to ethics committees and regulators within mandated timelines—complete, accurate, and on time ^[7]^
CGT products like CAR-T therapies involve complex, multi-step manufacturing: apheresis, transport, ex vivo modification, quality testing, infusion. Each step must be standardized and fully traceable—these are core inspection focal points.
Leukapheresis: Strictly follow protocol and SOPs; retain complete procedure records (time, operator, cell count, vital signs)
Product qualification: Retain Certificates of Analysis for each batch, verifying cGMP compliance and protocol-specified acceptance criteria ^[4]^
End-to-end traceability: Maintain detailed, auditable records across the entire product lifecycle—receipt, storage, transport, infusion, disposal/destruction. Every record must clearly identify responsible person, time, quantity, and status ^[2,4]^
Efficacy data drive trial conclusions. Whether using OS, ORR, or PFS, all endpoint data must be rigorously traceable. For imaging-dependent endpoints, standardized independent review is essential ^[8]^.
OS as primary endpoint: Death documentation is critical. Given potential difficulties obtaining official death certificates, inform subjects during consent and use multiple follow-up channels to verify survival status ^[4]^
Imaging-based endpoints (ORR/PFS) : Traceability is paramount. First, imaging assessment records must fully document evaluator, date, results, and any modifications. Second, all source images must be archived in PACS and fully traceable, allowing inspection authorities to reconstruct the entire evaluation. Third, IRC members must be properly qualified, and their assessments directly traceable to the specific reviewer and final report ^[4]^
Concomitant medication management: All prior and concomitant medications around cell infusion must strictly follow protocol allowances. Document everything—drug name, dose, timing, reason. Any protocol deviation must be immediately recorded with explanation and corrective actions ^[4]^
Equipment calibration: Centrifuges, scales/stadiometers, water baths, lab analyzers—all must undergo regular calibration and performance verification per SOPs. Calibrate critical parameters: centrifuge speed and temperature, scale accuracy for weight and height, water bath temperature. Retain complete calibration records and certificates ^[4]^
Subject protection is the bedrock of GCP—and a critical inspection "red line" ^[9]^.
Full ethical review coverage: Protocol, amendments, ICF updates, related documents—all must receive EC approval before implementation. No approval, no activity.
Proper informed consent: Process must be authentic, complete, traceable. Investigators must personally explain purpose, procedures, risks/benefits, alternatives, compensation—in language subjects understand. Subjects sign voluntarily only after demonstrating comprehension; retain signed original.
Long-term follow-up protections: CGT's potential long-term risks require comprehensive LTFU plans. Clearly outline privacy protections and explicitly inform subjects of their right to withdraw anytime.
China-specific requirements: China operates a "multi-departmental coordination + classified supervision" model. The NHC oversees clinical research filing and supervision, including institutional qualification and subject protection. CGT trial sites must be Grade A tertiary hospitals with professional teams and compliant ECs. No trial-related fees to subjects. Data retention: 30 years standard; offspring-related data permanently ^[10]^
Bottom line: Initiating without EC approval, improper ICF execution, coercing/inducing subjects, underreporting SAEs—these are serious GCP violations that can invalidate trials and trigger regulatory penalties.
The field is moving fast. The July 2025 "Gene and Cell Therapy Clinical Trials: Technological Breakthroughs and Regulatory Synergy" forum in Shenzhen showcased several innovative Chinese practices ^[11]^:
Gene therapy for hearing loss: Fudan University Eye & ENT Hospital demonstrated significant hearing improvement in congenital severe hearing loss using minimally invasive inner-ear injection of a dual-AAV system—a potential new paradigm for hereditary hearing disorders
Combination therapy exploration: The First Affiliated Hospital, Zhejiang University, is investigating CAR-T combined with allogeneic HSCT for high-risk hematologic malignancies, plus universal CD7 CAR-T development to address manufacturing time and cost challenges
IIT growth and challenges: China's IITs are proliferating rapidly, playing vital roles in rare diseases and refractory tumors. But challenges persist in multi-center organization, data reliability, and procedural standardization
The 5.3% success rate for CGT products reflects both inherent development risks and the critical importance of smart design and rigorous execution. Compliance isn't a box to check—it must be woven through every stage: design, subject selection, operations, data, safety reporting, product management.
Global regulators are adapting: the FDA through flexible CMC requirements and innovative design guidance; China through its comprehensive "Regulations on the Management of Clinical Research and Translational Application of New Biomedical Technologies."
For CGT professionals, the formula for success is clear: prioritize subject protection, stay current with evolving regulations, design scientifically sound protocols, and execute with unwavering GCP adherence—ensuring data is authentic, complete, and traceable.
That's how we bring more high-quality CGT therapies to patients worldwide, offering new hope for those battling devastating diseases.
References
[1] Elsallab M, et al. Mapping the Clinical Development Trajectory of Cell and Gene Therapy Products. Clin Pharmacol Ther. 2025;117(5):1264-1271.
[2] National Medical Products Administration. Good Clinical Practice. Announcement No. 57 of 2020.
[3] Center for Food and Drug Inspection, NMPA. Key Points and Judgment Principles for Drug Registration Inspections (Trial). 2021.
[4] GCP ClinPlus. Exploring On-site Inspection of CGT Clinical Trials. 2024.
[5] FDA. Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations (Draft). September 2025.
[6] FDA. Long-Term Follow-Up After Administration of Human Gene Therapy Products. January 2020.
[7] National Medical Products Administration. Standards and Procedures for Expedited Safety Reporting During Drug Clinical Trials. 2018.
[8] FDA. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. December 2018.
[9] ICH. ICH E6(R2): Good Clinical Practice. 2016.
[10] State Council, PRC. Regulations on the Management of Clinical Research and Translational Application of New Biomedical Technologies (State Council Decree No. 818). 2026.
[11] Shenzhen Medical Academy. Review of the Forum on Technological Breakthroughs and Regulatory Synergy in Gene and Cell Therapy Clinical Trials. July 2025.